Intermediate-Risk Prostate Cancer

Five-fraction stereotactic body radiotherapy proved noninferior to conventional radiotherapy with regard to biochemical or clinical failure for men with localized prostate cancer, according to randomized phase 3 study results.

Photon and proton beam radiation therapies conferred similar outcomes for men with localized prostate cancer, according to results of a randomized phase 3 trial.

Enzalutamide monotherapy demonstrated significant treatment response among men on active surveillance for low- or intermediate-risk localized prostate cancer, according to phase 2 study results published in JAMA Oncology.

Single-dose radiotherapy appeared safe and effective compared with hypofractionated stereotactic body radiotherapy among men with intermediate-risk prostate cancer, according to study findings published in JAMA Oncology.